 | Up a level |
Baertsch, Marc-Andrea, Mai, Elias K., Hielscher, Thomas, Bertsch, Uta, Salwender, Hans J., Munder, Markus, Fuhrmann, Stephan 
ORCID: 0000-0002-7785-2565, Duehrsen, Ulrich, Brossart, Peter, Neben, Kai, Schlenzka, Jana, Kunz, Christina, Raab, Marc S., Hillengass, Jens, Jauch, Anna, Seckinger, Anja, Hose, Dirk, Luntz, Steffen, Sonneveld, Pieter, Lokhorst, Henk, Martin, Hans, Goerner, Martin, Hoffmann, Martin, Lindemann, Hans-Walter, Bernhard, Helga, Blau, Igor W., Scheid, Christof, Besemer, Britta, Weisel, Katja C., Haenel, Mathias, Duerig, Jan and Goldschmidt, Hartmut
(2021).
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
Blood Cancer J., 11 (1).
LONDON:
SPRINGERNATURE.
ISSN 2044-5385
Baertsch, Marc-Andrea, Schlenzka, Jana, Lisenko, Katharina, Krzykalla, Julia, Becker, Natalia, Weisel, Katja, Noppeney, Richard, Martin, Hans, Lindemann, Hans W., Haenel, Mathias, Nogai, Axel, Scheid, Christof, Salwender, Hans ORCID: 0000-0001-7803-0814, Fenk, Roland, Graeven, Ullrich, Reimer, Peter, Schmidt-Hieber, Martin, Goerner, Martin, Schmidt-Wolf, Ingo G. H., Klein, Stefan, Ho, Anthony D., Goldschmidt, Hartmut and Wuchter, Patrick
(2017).
Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.
Eur. J. Haematol., 99 (1).
S. 42 - 51.
HOBOKEN:
WILEY.
ISSN 1600-0609
Baertsch, Marc-Andrea, Schlenzka, Jana, Mai, Elias K., Merz, Maximilian, Hillengass, Jens, Raab, Marc S., Hose, Dirk, Wuchter, Patrick, Ho, Anthony D. ORCID: 0000-0002-1656-0833, Jauch, Anna, Hielscher, Thomas, Kunz, Christina, Luntz, Steffen, Klein, Stefan, Schmidt-Wolf, Ingo G. H., Goerner, Martin, Schmidt-Hieber, Martin, Reimer, Peter, Graeven, Ullrich, Fenk, Roland, Salwender, Hans ORCID: 0000-0001-7803-0814, Scheid, Christof, Nogai, Axel, Haenel, Mathias, Lindemann, Hans W., Martin, Hans, Noppeney, Richard, Weisel, Katja and Goldschmidt, Hartmut
(2016).
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.
BMC Cancer, 16.
LONDON:
BMC.
ISSN 1471-2407
Goldschmidt, Hartmut, Baertsch, Marc-Andrea, Schlenzka, Jana, Becker, Natalia, Habermehl, Christina, Hielscher, Thomas, Raab, Marc-Steffen, Hillengass, Jens, Sauer, Sandra, Mueller-Tidow, Carsten, Luntz, Steffen, Jauch, Anna, Hose, Dirk, Seckinger, Anja, Brossart, Peter, Goerner, Martin, Klein, Stefan, Schmidt-Hieber, Martin, Reimer, Peter, Graeven, Ullrich, Fenk, Roland, Haenel, Mathias, Martin, Hans, Lindemann, Hans W., Scheid, Christoph, Nogai, Axel, Salwender, Hans, Noppeney, Richard, Besemer, Britta and Weisel, Katja . Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Mai, Elias K., Hielscher, Thomas, Bertsch, Uta, Schlenzka, Jana, Salwender, Hans J., Munder, Markus, Gerecke, Christian, Duehrsen, Ulrich, Brossart, Peter, Neben, Kai, Hillengass, Jens, Raab, Marc S., Merz, Maximilian, Baertsch, Marc-Andrea, Jauch, Anna, Hose, Dirk, Martin, Hans, Lindemann, Hans-Walter, Blau, Igor W., Scheid, Christof, Weisel, Katja C. and Goldschmidt, Hartmut (2019). Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma. Leukemia, 33 (1). S. 258 - 262. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551